Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 25;9(12):2543.
doi: 10.3390/cells9122543.

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis

Affiliations

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis

Tilman Robinson et al. Cells. .

Abstract

The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS.

Keywords: B cell-activating factor (BAFF); MRZ reaction (MRZR); chemokine CXC ligand 13 (CXCL-13); chitinase-3-like protein 1 (CHI3L1); glial fibrillary acidic protein (GFAP); neurofilament light chain (NfL); primary progressive multiple sclerosis (PPMS); soluble B cell maturation antigen (sBCMA); soluble transmembrane activator and CAML interactor (sTACI).

PubMed Disclaimer

Conflict of interest statement

T.R. received travel grants from Bayer Vital GmbH, Biogen Idec, and Novartis. A.A. received research funding from DMSG, travel grants from Biogen Idec, and institutional research grants from Merck Serono and Novartis, all outside the submitted study. T.B. has nothing to disclose. E.M. received honorarium from Roche, Novartis, Sanofi-Aventis, Biogen Idec, and Bioeq, and grant support from Novartis, Sanofi-Aventis, and Merck Serono. M.O. gave scientific advice for Axon, Roche, Fujirebio, and Biogen Idec. U.K.Z. received speaker fees, travel compensation, and/or his section received research support from Alexion, Almirall, Bayer Health Care, Biogen Idec, Celgene, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, and Teva, and grants from the German Ministry for Education and Research (BMBF), German Ministry for Economy (BMWi), Deutsche Forschungsgemeinschaft (DFG), and European Union (EU), outside the submitted work. R.D. received lecture fees by Roche and travel grants from Biogen Idec. H.T. reports funding for research projects, lectures, and travel from Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva, and received research support from DMSG and BMBF. S.R. reports receiving consulting and lecture fees, research grants, and research support from Baxter, Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, R.G., Sanofi-Aventis, and Teva. S.R. indicates that he is a founding executive board member of ravo Diagnostika GmbH (Oltmannsstrasse 5, D-79100 Freiburg, Germany), which sells in vitro diagnostic medical devices for the detection of infectious diseases and paraneoplastic autoantibodies. A.H. has nothing to disclose.

Figures

Figure 1
Figure 1
CXCL-13: chemokine CXC ligand 13; CSF: cerebrospinal fluid; BAFF: B cell-activating factor; MRZR-: primary progressive multiple sclerosis patients with no more than one positive MRZ antibody index; MRZR+: primary progressive multiple sclerosis patients with at least two positive MRZ antibody indices.
Figure 2
Figure 2
sBCMA: soluble B cell maturation antigen; CSF: cerebrospinal fluid; sTACI: soluble transmembrane activator and CAML interactor; MRZR-: primary progressive multiple sclerosis patients with no more than one positive MRZ antibody index; MRZR+: primary progressive multiple sclerosis patients with at least two positive MRZ antibody indices.

Similar articles

Cited by

References

    1. Antel J., Antel S., Caramanos Z., Arnold D.L., Kuhlmann T. Primary progressive multiple sclerosis: Part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 2012;123:627–638. doi: 10.1007/s00401-012-0953-0. - DOI - PubMed
    1. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996;46:907–911. doi: 10.1212/WNL.46.4.907. - DOI - PubMed
    1. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903–912. doi: 10.1016/S1474-4422(07)70243-0. - DOI - PubMed
    1. Owens G.P., Bennett J.L., Gilden D.H., Burgoon M.P. The B cell response in multiple sclerosis. Neurol. Res. 2006;28:236–244. doi: 10.1179/016164106X98099. - DOI - PubMed
    1. Krumbholz M., Derfuss T., Hohlfeld R., Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 2012;8:613–623. doi: 10.1038/nrneurol.2012.203. - DOI - PubMed

Publication types

Substances